Computational scientists design a new IL-2 cancer drug and spin it out into a biotech startup
One of the Holy Grails in the booming immuno-oncology research field right now involves finding an IL-2 drug that can be used safely and effectively to combat cancer, without the immense toxicity that has largely sidelined the original IL-2 Proleukin. Bristol-Myers Squibb paid Nektar $1.85 billion in upfront cash to partner on NKTR-214 — which has since come under a cloud of uncertainty over flailing response rates in their key demonstration study combining it with Opdivo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
